Rosuvastatin suppresses the oxidative response in the venous limb of an arteriovenous fistula and enhances the fistula blood flow in diabetic rats

Shi-Yuan Fang, Jun-Neng Roan, Yu Lin, Chin-Hsin Hsu, Shih Wei Chang, Chein Chi Huang, Yu-Chuan Tsai, Chen Fuh Lam

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: The blood flow in the arteriovenous (AV) fistula is significantly reduced in diabetic patients. Statins are known to mediate pleiotropic effects in the vascular endothelium and attenuate inflammatory responses. This study tested the vascular protective effect of rosuvastatin in an experimental model of AV fistula. Methods: One week after the induction of diabetes mellitus (DM) in rats, a fistula was created in the abdominal aorta and inferior vena cava. Rats received placebo or rosuvastatin (15 mg/kg/day) in chow for 2 weeks. The blood flow in the venous segments of the fistula was measured. The expression of proinflammatory genes and the generation of superoxide in the venous fistula were examined. Results: The blood flow and luminal diameter of the AV fistula was significantly enhanced in animals treated with rosuvastatin. Rosuvastatin attenuated the expression of inducible nitric oxide synthase, NADPH oxidase, and monocyte chemotactic protein-1 in the fistula. The levels of superoxide anions and proinflammatory cytokines were also suppressed in rosuvastatin-treated animals. Neointimal formation in the AV fistula was not affected following treatment with rosuvastatin. Conclusions: We demonstrated that rosuvastatin improves luminal dilatation and blood flow in the AV fistula of subjects with DM. These vascular protective effects of rosuvastatin are most likely mediated by the attenuation of proinflammatory activities in the remodeled vasculature.

Original languageEnglish
Pages (from-to)81-89
Number of pages9
JournalJournal of Vascular Research
Volume51
Issue number2
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Arteriovenous Fistula
Fistula
Extremities
Superoxides
Blood Vessels
Diabetes Mellitus
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Rosuvastatin Calcium
Chemokine CCL2
NADPH Oxidase
Abdominal Aorta
Vascular Endothelium
Inferior Vena Cava
Nitric Oxide Synthase Type II
Dilatation
Theoretical Models
Placebos
Cytokines
Gene Expression

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

@article{041ddea869bb49229d62a0e31b7305a2,
title = "Rosuvastatin suppresses the oxidative response in the venous limb of an arteriovenous fistula and enhances the fistula blood flow in diabetic rats",
abstract = "Objective: The blood flow in the arteriovenous (AV) fistula is significantly reduced in diabetic patients. Statins are known to mediate pleiotropic effects in the vascular endothelium and attenuate inflammatory responses. This study tested the vascular protective effect of rosuvastatin in an experimental model of AV fistula. Methods: One week after the induction of diabetes mellitus (DM) in rats, a fistula was created in the abdominal aorta and inferior vena cava. Rats received placebo or rosuvastatin (15 mg/kg/day) in chow for 2 weeks. The blood flow in the venous segments of the fistula was measured. The expression of proinflammatory genes and the generation of superoxide in the venous fistula were examined. Results: The blood flow and luminal diameter of the AV fistula was significantly enhanced in animals treated with rosuvastatin. Rosuvastatin attenuated the expression of inducible nitric oxide synthase, NADPH oxidase, and monocyte chemotactic protein-1 in the fistula. The levels of superoxide anions and proinflammatory cytokines were also suppressed in rosuvastatin-treated animals. Neointimal formation in the AV fistula was not affected following treatment with rosuvastatin. Conclusions: We demonstrated that rosuvastatin improves luminal dilatation and blood flow in the AV fistula of subjects with DM. These vascular protective effects of rosuvastatin are most likely mediated by the attenuation of proinflammatory activities in the remodeled vasculature.",
author = "Shi-Yuan Fang and Jun-Neng Roan and Yu Lin and Chin-Hsin Hsu and Chang, {Shih Wei} and Huang, {Chein Chi} and Yu-Chuan Tsai and Lam, {Chen Fuh}",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000357619",
language = "English",
volume = "51",
pages = "81--89",
journal = "Journal of Vascular Research",
issn = "1018-1172",
publisher = "S. Karger AG",
number = "2",

}

Rosuvastatin suppresses the oxidative response in the venous limb of an arteriovenous fistula and enhances the fistula blood flow in diabetic rats. / Fang, Shi-Yuan; Roan, Jun-Neng; Lin, Yu; Hsu, Chin-Hsin; Chang, Shih Wei; Huang, Chein Chi; Tsai, Yu-Chuan; Lam, Chen Fuh.

In: Journal of Vascular Research, Vol. 51, No. 2, 01.01.2014, p. 81-89.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rosuvastatin suppresses the oxidative response in the venous limb of an arteriovenous fistula and enhances the fistula blood flow in diabetic rats

AU - Fang, Shi-Yuan

AU - Roan, Jun-Neng

AU - Lin, Yu

AU - Hsu, Chin-Hsin

AU - Chang, Shih Wei

AU - Huang, Chein Chi

AU - Tsai, Yu-Chuan

AU - Lam, Chen Fuh

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective: The blood flow in the arteriovenous (AV) fistula is significantly reduced in diabetic patients. Statins are known to mediate pleiotropic effects in the vascular endothelium and attenuate inflammatory responses. This study tested the vascular protective effect of rosuvastatin in an experimental model of AV fistula. Methods: One week after the induction of diabetes mellitus (DM) in rats, a fistula was created in the abdominal aorta and inferior vena cava. Rats received placebo or rosuvastatin (15 mg/kg/day) in chow for 2 weeks. The blood flow in the venous segments of the fistula was measured. The expression of proinflammatory genes and the generation of superoxide in the venous fistula were examined. Results: The blood flow and luminal diameter of the AV fistula was significantly enhanced in animals treated with rosuvastatin. Rosuvastatin attenuated the expression of inducible nitric oxide synthase, NADPH oxidase, and monocyte chemotactic protein-1 in the fistula. The levels of superoxide anions and proinflammatory cytokines were also suppressed in rosuvastatin-treated animals. Neointimal formation in the AV fistula was not affected following treatment with rosuvastatin. Conclusions: We demonstrated that rosuvastatin improves luminal dilatation and blood flow in the AV fistula of subjects with DM. These vascular protective effects of rosuvastatin are most likely mediated by the attenuation of proinflammatory activities in the remodeled vasculature.

AB - Objective: The blood flow in the arteriovenous (AV) fistula is significantly reduced in diabetic patients. Statins are known to mediate pleiotropic effects in the vascular endothelium and attenuate inflammatory responses. This study tested the vascular protective effect of rosuvastatin in an experimental model of AV fistula. Methods: One week after the induction of diabetes mellitus (DM) in rats, a fistula was created in the abdominal aorta and inferior vena cava. Rats received placebo or rosuvastatin (15 mg/kg/day) in chow for 2 weeks. The blood flow in the venous segments of the fistula was measured. The expression of proinflammatory genes and the generation of superoxide in the venous fistula were examined. Results: The blood flow and luminal diameter of the AV fistula was significantly enhanced in animals treated with rosuvastatin. Rosuvastatin attenuated the expression of inducible nitric oxide synthase, NADPH oxidase, and monocyte chemotactic protein-1 in the fistula. The levels of superoxide anions and proinflammatory cytokines were also suppressed in rosuvastatin-treated animals. Neointimal formation in the AV fistula was not affected following treatment with rosuvastatin. Conclusions: We demonstrated that rosuvastatin improves luminal dilatation and blood flow in the AV fistula of subjects with DM. These vascular protective effects of rosuvastatin are most likely mediated by the attenuation of proinflammatory activities in the remodeled vasculature.

UR - http://www.scopus.com/inward/record.url?scp=84892388537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892388537&partnerID=8YFLogxK

U2 - 10.1159/000357619

DO - 10.1159/000357619

M3 - Article

C2 - 24434545

AN - SCOPUS:84892388537

VL - 51

SP - 81

EP - 89

JO - Journal of Vascular Research

JF - Journal of Vascular Research

SN - 1018-1172

IS - 2

ER -